These new models are specially trained to recognize when an LLM is potentially going off the rails. If they don’t like how an interaction is going, they have the power to stop it. Of course, every ...

Q4 2026 Earnings Call March 4, 2026 5:00 PM ESTCompany ParticipantsGunnar Hansen - Director of Investor RelationsPeter Gassner ...

A recent meeting of the 2025-26 season of the Fredonia Shakespeare Club was hosted at the home of Judi Lutz Woods. President Karin Cockram welcomed Club members to the meeting. After a brief business ...

As Chief Information Security Officers (CISOs) and security leaders, you are tasked with safeguarding your organization in an ...

Safe coding is a collection of software design practices and patterns that allow for cost-effectively achieving a high degree ...

Introduction The proliferation of deepfake technology, synthetic media generated using advanced artificial intelligence techniques, has emerged as a ...

According to Precedence Research, the global software market size accounted for USD 823.92 billion in 2025 and is predicted ...

JAKARTA, Jan 26 (Reuters) - The death toll from a landslide that hit Indonesia's West Java province at the weekend rose to 17 on Monday, the country's disaster mitigation agency said, with dozens ...

Application Writing is the process of drafting a formal request to someone in an authoritative position to seek permission, ask for something, or apply for a post. An application is written in the ...

SUNNYVALE, Calif. & MALVERN, England--(BUSINESS WIRE)--Azul, the only company 100% focused on Java, today announced the acquisition of Payara, a global provider of enterprise-grade solutions for ...

Strategic acquisition bolsters Azul’s Java platform with complementary products, deep Java expertise and accelerated go-to-market capabilities Azul, the only company 100% focused on Java, today ...

The FDA is said to be making a U-turn on uniQure’s one-time gene therapy candidate for Huntington’s disease despite the treatment being hailed as a game changer. The FDA no longer agrees that data ...